Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular versus oral steroid bridging therapy in active rheumatoid arthritis
ChiCTR2400093187Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of betamethasone and corticosteroids in rheumatoid arthritis (RA) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Disease remission rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
betamethasonecorticosteroids
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2400093187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093187.